Crystalys Therapeutics

Crystalys Therapeutics announced $130M in Series B financing on July 22, 2026. Crystalys Therapeutics raised an oversubscribed $130 million Series B led by Frazier Life Sciences to advance clinical development and commercialization preparation of dotinurad for gout.

Round details

The financing includes backing from Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds. The company did not publish a valuation with the announcement.

• Round: Series B
• Capital announced: $130M
• Headquarters: San Diego, CA

How the company plans to use the capital

The company said proceeds are expected to support ongoing clinical development of dotinurad and preparation for commercialization. The release also said the funding provides operational runway through multiple anticipated clinical and regulatory milestones.

Why this matters for GTM teams

Dotinurad has regulatory approval in Japan, China, the Philippines, Taiwan and Thailand, and the company has two ongoing Phase 3 registration-directed trials, RUBY and TOPAZ, alongside an ongoing Phase 2 study, AMETHYST.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Crystalys Therapeutics Series B announcement.